Salute e Benessere

SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER…

SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEMPRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 20 November 2025, 6:00 pm CETGhent, Belgium, 20 November 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a...
Nasdaq GlobeNewswire
20/11/2025

GENFIT announces effectiveness of voluntary delisting of American Depositary…

Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); November 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT),a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Select Market (“Nasdaq”) has become effective. Each ADS represents one ordinary share of...
Nasdaq GlobeNewswire
20/11/2025

Radiology AI Market worth $2.27 billion by 2030 with 24.5% CAGR |…

Browse in-depth TOC on "Radiology AI Market" Browse in-depth TOC on "Radiology AI Market" 150 - Tables50 - Figures 450 - Pages By indication,the radiology AI market is segmented into oncology, cardiology, neurology, pulmonology/respiratory diseases, orthopedics, women's health, and other indications. The oncology segment is expected to register the highest CAGR in the radiology AI market, driven by the rapidly increasing global cancer burden and the significant...
PR Newswire
20/11/2025

PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at…

r/r B-NHL r/r B-NHL Safety:PMB-CT01 demonstrated an exceptionally favorable tolerability profile. No Grade ˃1 Cytokine Release Syndrome (CRS) and no Grade ˃1 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Efficacy:All the first 7 patients achieved a Complete Response (CR) at 1–3 months post-infusion, including those previously treated with CD19 CAR T therapy and those with CD19-negative disease. Durability:Remissions have remained ongoing for up to 32+...
PR Newswire
20/11/2025

Genomics Market worth $85.09 billion by 2030 with 12.6% CAGR |…

Browse in-depth TOC on "Genomics Market" Browse in-depth TOC on "Genomics Market" 350 - Tables 50 - Figures 310 - Pages By offerings,the genomics market is segmented into products and services. The products segment accounted for the largest share of the genomics market in 2024. The large share of the products segment can be attributed to innovations in genomics technology, such as long-read sequencing (LRS), single-cell genomics, and CRISPR technology, which have expanded...
PR Newswire
20/11/2025

Waterdrop Filter Launches Black Friday, Cyber Monday Sale with Discounts Across…

The Waterdrop Filter K6 Reverse Osmosis System, discounted to $499 from $799, is the first tankless RO system with instant hot water. Recognized by major media as one of 2024's best under-sink systems, it offers a 600G flow rate, five-stage filtration, and built-in safety features, including heating overtime protection. Ideal for families with infants or seniors, the K6 provides instant hot or cold water while preventing limescale buildup. The Waterdrop Filter K6 Reverse Osmosis System ,...
PR Newswire
20/11/2025

Oxford-Harrington Rare Disease Centre Announces 2025 Scholars Advancing…

Rare diseases affect an estimated 500 million people worldwide—half of whom are children. Yet, fewer than 5% of the 7,000 known rare diseases have approved treatments. The OHC, a unique partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is on a mission to accelerate progress by combining philanthropy, world-class science and entrepreneurial drug development. Rare diseases affect an estimated 500 million people...
PR Newswire
20/11/2025

From Inspiration to Reality: The LEPAS Design Team Decodes the Birth of "Leopard…

Interior Design: Serenity and Comfort Under the 'Skyline'The interior represents the essence of elegance and the spirit of "Leopard Aesthetics." Inspired by a tranquil Skyline, the wrap-around cockpit isolates urban noise and sets a calming atmosphere. The central Waterfall Screen flows like natural currents, extending smooth visual lines. A soft, wave-textured instrument panel feels warm and soothing, while pebble-patterned speaker grilles and floating stone accents pair with ambient…
PR Newswire
20/11/2025

ViVac Appoints Keren Leshem as Chief Executive Officer, Strengthening Leadership…

Leshem, a World Economic Forum Technology Pioneer CEO, has been recognized by Forbes and Entrepreneur as one of the most influential leaders. She brings almost three decades of experience leading clinical-stage life science companies and translating breakthrough research into commercial success. Leshem, aWorld Economic Forum Technology Pioneer CEO, has been recognized byForbesandEntrepreneuras one of the most influential leaders. She brings almost three decades of experience leading...
PR Newswire
20/11/2025

HitGen Receives New Funding to Discover Novel Therapeutics for Underserved…

"We are honored to continue this important work with support from the Gates Foundation," said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen Inc. "We look forward to engaging with other world-leading philanthropic and academic institutions to deliver transformative solutions for patients with unmet medical needs." "We are honored to continue this important work with support from the Gates Foundation," saidDr.Jin Li, Chairman of the Board and…
PR Newswire
20/11/2025

Kolmar Korea Named Among TIME's World's Best Companies in Sustainable Growth…

Only ten Korean companies made the list this year — down by 13 compared to last year — and Kolmar Korea was the only Korean cosmetics company to be ranked for two consecutive years. Only ten Korean companies made the list this year — down by 13 compared to last year — and Kolmar Korea was the only Korean cosmetics company to be ranked for two consecutive years. The evaluation was based on three equally weighted factors —revenue growth, financial stability, and environmental impact— on a...
PR Newswire
20/11/2025

ZINZINO AB (PUBL.): Share subscription due to warrants

The total number of B shares increased by 42,000 to 31,206,148. The total number of shares after the increase was 36,319,540. The dilution amounted to 0.12 percent. Zinzino's share capital increased to SEK 3,631,954. The total number of B shares increased by 42,000 to 31,206,148. The total number of shares after the increase was 36,319,540. The dilution amounted to 0.12 percent. Zinzino's share capital increased toSEK 3,631,954. For more information: Dag Bergheim Pettersen CEO...
PR Newswire
20/11/2025

Evaxion announces positive data for lead antigens in cytomegalovirus (CMV)…

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigensEvaxion’s proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen demonstrates superior performance compared to the traditional gB antigen, including enhanced CMV neutralization...
Nasdaq GlobeNewswire
20/11/2025

CapVest recapitalizes Curium to accelerate its growth strategy, marking the…

Curium and CapVest have announced the recapitalization of Curium via a new Continuation Vehicle The transaction values Curium at circa $7 billion, representing the largest transaction in nuclear medicine globally The recapitalization will accelerate Curium’s strategy to launch innovative, life-changing diagnostic and therapeutic solutions for cancer patients around the worldBOSTON, Nov.20, 2025(GLOBE NEWSWIRE) -- Curium, a leading producer of radiopharmaceuticals, and CapVest...
Nasdaq GlobeNewswire
20/11/2025

Lappset launches new Prime collection

Industrial News Service
20/11/2025

NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as…

More than 80% of late-stage pipeline candidates are metabolic and fibrotic-targeted therapies-ranging from GLP-1 agonists, FGF21 analogues, PPAR agonists, THR-β agonists, ACC inhibitors, and dual agonists-positioning the MASH landscape for unprecedented transformation between 2025 and 2033. More than 80% of late-stage pipeline candidates are metabolic and fibrotic-targeted therapies-ranging fromGLP-1 agonists, FGF21 analogues, PPAR agonists, THR-β agonists, ACC inhibitors, and dual agonists...
PR Newswire
20/11/2025

Dreame's Biggest Black Friday Deals of the Year - Save Up to £450 on our…

Unlock unbeatable deals of the year on Dreame's top-rated products for a smarter, cleaner home Dreame Aqua10 Ultra Roller CompleteEfficient, Thorough Cleaning The Dreame Aqua10 Ultra Roller Complete features ProLeap™ retractable robot legs to tackle thresholds and uneven terrain up to8 cm. AquaRoll™ technology ensures self-cleaning with fresh water and separates dirty water to prevent re-contamination. Its FluffRoll™ technology, rotating at 1,000 RPM,...
PR Newswire
20/11/2025

Alvotech and Advanz Pharma Receive Marketing Approval Across the European…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission (EC) has granted marketing authorizations in the European Economic Area (EEA) for Gobivaz®, Alvotech’s biosimilar to...
Nasdaq GlobeNewswire
20/11/2025

IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director…

PRESS RELEASELondon, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos Paya as Non-Executive Director.Carlos has a distinguished track record of leadership spanning academic medicine and the biopharmaceutical industry, with deep expertise in drug development and commercial strategy across early-stage start-ups to large-cap pharmaceutical...
Nasdaq GlobeNewswire
20/11/2025

Smartee Deepens Its Strategy for Central Asia and Russia in 2025

In addition to its exhibition presence, Smartee continued its educational mission by hosting the GS Mandibular Repositioning Academic Forum in Almaty. The forum featured in-depth training sessions and live case discussions, offering local orthodontists insights into Smartee's pioneering approach to mandibular repositioning and functional orthodontic therapy. This initiative strengthened professional ties and solidified Smartee's role in advancing clinical practices in the region. In addition…
PR Newswire
20/11/2025

Third quarter 2025 update: IBA is highly confident to meet FY2025 guidance, and…

Louvain-la-Neuve, Belgium, 20 November 2025- IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, shares its business update for the third quarter of 2025.Group Overview Equipment order intake at €195 millionas of Q3 2025 (+6% vs. last year) with a strong contribution from IBA Technologies (+22%) driven by RadioPharma Solutions, and four Proteus ® ONE solutions sold within IBA Clinical. Equipment and Services backlog stable at €1.3 billion,...
Nasdaq GlobeNewswire
20/11/2025

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024Cash and cash equivalents of €143.5 million at end of September 2025Financial flexibility enhanced with successful debt refinancing in October 2025 1 Lyme disease Phase 3 study VALOR on trackUpdated 2025 financial outlook confirmed 1Saint-Herblain (France), November 20, 2025 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported...
Nasdaq GlobeNewswire
20/11/2025

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by…

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc 1 Peak sales guidance upgraded for Kisqali and Scemblix; Novartis now has eight de-risked, in-market assets with USD 3-10 billion peak sales potential15+ potentially submission-enabling readouts expected in the next two years to fuel long-term growth Pipeline includes 30+ potential high-value medicines, with...
Nasdaq GlobeNewswire
20/11/2025

AIRS Medical Continues Swift Expansion Through Europe, the Middle East, and…

SwiftMR: To Europe and BeyondEstablished in 2024, AIRS Medical Europe GmbH has been steadily spreading SwiftMR's significant efficiency and quality improvements throughout the European healthcare market. SwiftMR: To Europe and BeyondEstablished in 2024, AIRS Medical Europe GmbH has been steadily spreading SwiftMR's significant efficiency and quality improvements throughout the European healthcare market. Already, AIRS Medical has nurtured several partnerships inEurope, including: ...
PR Newswire
20/11/2025
Altri  Comunicati